INNOVATIVE DELIVERY PLATFORM FOR NOVEL PRODUCT FORMULATIONS

Company

MyX Therapeutics is a unique enabling mucosal delivery platform technology company to focus on a product development licensing partnership business model. Our technology is a patented biodegradable delivery-adhesive nanoparticle which allows our team to create market sector differentiating novel products for delivery of ophthalmic, sublingual & intranasal, vaginal and IR of drug.

Our initiated or intended targeted therapeutic product development BD partnerships focus may include, but not limited to:

HUMAN

Ophthalmic

  • Antibacterial
  • Antiviral
  • Antifungal
  • Acute Pain (post-surgery)
  • Dry eye
  • Allergy
  • Glaucoma
  • OTC Eye Nutrient & Supplement
  • OTC Eye Hydration & Lubrication (artificial tears)

Sublingual

  • GI Therapies
  • Dry mounth
  • Antibacterial
  • Antiviral
  • Oral Pain (Post surgery)
  • Acute & Chronic Pain
  • Hormonal Replacement
  • OTC Homeopathic supplements
  • OTC Dental Oral Rinse
  • OTC Oral Pain
  • OTC General Health Nutrient & Supplement

Intranasal

  • Antibacterial
  • Antiviral
  • Acute Pain (migraine)
  • Hormonal Replacement
  • Depression & Anxiety Therapies
  • Neurological diseases
  • Addictive Therapies (nicotine, etc.)
  • Vaccines
  • OTC Allergy Therapies
  • OTC Nasal Hydration & Lubrication

Cannabis Market sector

  • GI Therapies
  • Nausea
  • Acute & Chronic Pain
  • Epilepsy
  • Neurological diseases

VETERINARY

  • Antibacterial
  • Antiviral
  • Antifungal (aquaculture)
  • Chronic Pain
  • Dry eye
  • Allergy
  • Anxiety & weight control
  • Aquaculture Nutrient & Supplements
  • Vaccines

Our business model is to create product development partnerships in both human & veterinary product field allowing a platform for Brand Creation across a market sector by focusing on the following core technology advantage

  • Enabling Patent Extension Strategy Opportunity
  • Generic Product Conversion:
  • Premium Market Differentiation Leadership Strategy
  • Decrease Dose (Improving Safety & Efficacy Therapy Windows)
  • Decrease Dose Frequency (Patient Compliance & Effectiveness of Therapy)
  • New & Effective Routes of Administration
  • Join venture applications enabling technology to create a define market differentiation in medical cannabis sector

MANAGEMENT / ÉQUIPE DE DIRECTION

Gregory L. White, M. Sc.

President & CEO, Founder
Président & Chef de la direction, Fondateur

BIO

Gregory White is Founder, President, and CEO at MyX Therapeutics.  Mr. White is a “hands-on” entrepreneur who enjoys the collaborative challenge of bringing creative ideas to fruition within the biotech and environmental technology fields.  He is credited for his successful strategic leadership focused high-risk innovative companies. He has managed project study coordinator for international IFPMA/WHO/DOD global pandemic readiness committee.  He has founded and managed a series of start up companies through successful exits: Innergy; Biomass Strategies; Ecopia Bioscience (M&A to create Thallion), and; Intellivax – ID Biomedical (successful strategic and product development of an intranasal mucosal platform delivery technology which culminated in the acquisition by GSK in 2005 for 1.5$ Billion).  He has held various management and executive positions with Univax (through M&A to create NABI); Connaught Labs (acquired by PMC); Schering (R&D Biotechnology & Biochemistry Division). Mr. White holds a Masters degree in Biochemistry/Molecular Biology from University of Arkansas for Medical Sciences and a second Masters degree Zoology/Biochemistry from University of Arkansas, Fayetteville.

Frank Gu, Ph.D

CSO, Founder
Chef des affaires scientifiques, Fondateur

BIO

Dr Frank Gu is a founder & Chief Scientific Officer of MyX Therapeutics and a Professor in the Department of Chemical Engineering and Applied Chemistry at the University of Toronto. Prior to joining the University of Toronto in July 2018, Dr. Gu was an Associate Professor and Canada Research Chair in Nanotechnology Engineering at the University of Waterloo. Dr. Gu leads a frontier research group specializes in Nanotechnology Engineering, with important advances in medical and life science applications. Dr. Gu has authored and co-authored more than 200 journal and conference publications, as well as 25 U.S. and World patents and applications. Dr. Gu received postdoctoral training at MIT (2008) and holds a Ph.D. in chemical engineering from Queen’s University (2006).

Veronique Bougie, M.Sc. CLP

Chief Operating Officer
Chef des opérations

BIO

Veronique Bougie has been involved in the creation and management of four start-ups. Previously she was Director, Business Development in life science, Univalor LP, the tech transfer office of the Université de Montreal and its affiliated institutions. Veronique is a Certified Licensing Professional and holds a M.Sc. in virology and immunology at INRS-Armand-Frappier, undertook several trainings in intellectual property management & strategy and completed the Rutgers Business School Executive Education’s MiniMBA BioPharma Innovation.

Shengyan (Sandy) Liu, Ph.D

Senior Scientist
Scientifique principal

BIO

Dr. Shengyan (Sandy) Liu is a co-inventor of MyX Therapeutics platform technology. During his PhD at University of Waterloo, he co-invented and developed the nanoparticle technology as a drug delivery platform to target various mucosal tissues in the body. Sandy received Mitacs Accelerate fellowship support from AmorChem to continue developing and advancing the technology towards clinical trials and beyond after his PhD. He has authored and co-authored 8 journal publications and presented his work at more than 30 research conferences.  

BOARD OF DIRECTORS /
CONSEIL D’ADMINISTRATION

Gregory L. White, M. Sc.

President & CEO, Founder
Président & Chef de la direction, Fondateur

BIO

Gregory White is Founder, President, and CEO at MyX Therapeutics.  Mr. White is a “hands-on” entrepreneur who enjoys the collaborative challenge of bringing creative ideas to fruition within the biotech and environmental technology fields.  He is credited for his successful strategic leadership focused high-risk innovative companies. He has managed project study coordinator for international IFPMA/WHO/DOD global pandemic readiness committee.  He has founded and managed a series of start up companies through successful exits: Innergy; Biomass Strategies; Ecopia Bioscience (M&A to create Thallion), and; Intellivax – ID Biomedical (successful strategic and product development of an intranasal mucosal platform delivery technology which culminated in the acquisition by GSK in 2005 for 1.5$ Billion).  He has held various management and executive positions with Univax (through M&A to create NABI); Connaught Labs (acquired by PMC); Schering (R&D Biotechnology & Biochemistry Division). Mr. White holds a Masters degree in Biochemistry/Molecular Biology from University of Arkansas for Medical Sciences and a second Masters degree Zoology/Biochemistry from University of Arkansas, Fayetteville.

Maxime Ranger, Ph.D, MBA

General Partner, AmorChem
Associé principal, AmorChem

BIO

Dr Maxime Ranger is General Partner at AmorChem. He is Director of the Board of portfolio companies, such as Inversago Pharma, SemaThera, Mperia and MyX Therapeutics. Dr Ranger founded and managed a series of startup companies within Quebec’s ecosystem: Inversago Pharma (2015-present), gIcare pharma (2011-2015) with more than 10M$ raised in venture capital and GInova Pharma (2008-2011). Previously, he held management positions at Labopharm (2001-2003, acquired by Paladin, became Endo), Bioxalis Medica (2003-2004, acquired by Procyon, became Ambrillia) and Ecopia Bioscience (2004-2008, became Thallion, acquired by Bellus Health). Mr. Ranger has completed an Executive MBA at UQAM and Université Paris-Dauphine (2012), performed a postdoctoral fellow at Stanford University (2001) and holds a Ph.D. in chemistry, Material Sciences, from Laval University (2000).

Seed Investor / Investisseur

News / Nouvelles

Press Release - December 17th, 2018

AmorChem Spins out Its Muco-Adhesive Nanoparticle Delivery Platform into MyX Therapeutics, with 450,000$ Seed Investment.

Montreal (BusinessWire) – November 29, 2018 – AmorChem announces today the creation of MyX Therapeutics Inc, its sixth spin-off company focusing on MyX-001, a biodegradable muco-adhesive nanoparticle delivery platform, capable of sustained drug releases for ophthalmic use and other mucosa-based deliveries. All rights to the MyX-001 technology initially held by AmorChem have been transferred to MyX Therapeutics, with a first seed investment of 450,000$. This capital will allow MyX to clinch its first deals with commercial partners, targeting primarily ocular diseases in both animal and human health.

Developed by University of Waterloo researchers Dr Frank Gu, Dr. Lyndon Jones, and Dr. Sandy Liu, the MyX-001 technology demonstrated great potential of this platform for local mucosal targeted administration. “This delivery system can be tuned according to drug properties to maximize the drug loading in nanoparticles and provide sustained release for maximal drug efficacy. It combines the key advantages of our competitors in a single drug delivery platform,” explains Dr. Inès Holzbaur, co-founder and managing partner, AmorChem.

“This technology holds great promise to improve patient health through the novel delivery of ophthalmic drug therapeutics. Our partnership with AmorChem is a great example of visionary capital and innovative research coming together to create a disruptive technology start-up company like MyX,” adds Scott Inwood, Director of Commercialization, University Waterloo.

“MyX-001 is a platform uniquely designed to provide market differentiation to numerous highly effective generic API drugs by allowing increase compliance with the potential for 1x/day or 2x/week dosing, while providing hydration and lubrication to localize mucosal tissue.  Additionally, MyX-001 may allow for an increase safety threshold for enabling new drugs or establish drug’s profile, as it has been shown in our initial animal models that significantly less drug may necessary to obtain the same efficacious results,” comments Gregory L. White, CEO, MyX Therapeutics.

MANAGEMENT TEAM OF MyX THERAPEUTICS

Upon creation of MyX Therapeutics, AmorChem appointed Gregory L. White, M.Sc. (Zoology), M.Sc. (Biochem/Mol. Biol.), as President and CEO, Dr. Frank Gu, Ph.D., as Chief Scientific Officer and, Véronique Bougie as Chief Operating Officer of the company. Their mandate is to expand the use of MyX-001 delivery platform to various medical indications and other application unrelated to health.  

ABOUT MyX THERAPEUTICS INC

MyX Therapeutics (www.myxthera.com) is a unique enabling mucosal delivery platform technology company to focus on a product development licensing partnership business model. Its technology is a patented biodegradable delivery-adhesive nanoparticle which allows its team to create market sector differentiating novel products for various routes of administration, including ophthalmic, sublingual & intranasal, vaginal and gastrointestinal deliveries.

ABOUT AMORCHEM

AmorChem (www.amorchem.com) is a leading, early-stage, venture capital fund located in Montreal focused on creating promising life science companies from technologies originating primarily from Quebec-based universities and research centres. With 95M$ under management, AmorChem targets disruptive technologies which provide huge impact on patients’ health and foster their path up to clinical stage.

Media contacts:

Inès Holzbaur, Ph.D.

Co-founder and managing partner, AmorChem

T:  +1-514-849-7696

E: ines@amorchem.com

 

Gregory L. White, M.Sc., M.Sc.

President and CEO, MyX Therapeutics Inc.

T:  +1-514-797-8833

E:  greg@myxthera.com

Communiqué de Presse - 17 Décembre 2018

AMORCHEM TRANSFÈRE SA PLATEFORME DE NANOPARTICULES MUCO-ADHÉSIVES DANS MyX THERAPEUTIQUE, AVEC 450 000$.

Montréal (BusinessWire) – 29 novembre, 2018 – AmorChem annonce aujourd’hui la création de MyX Therapeutics Inc, sa sixième entreprise dérivée, axée sur MyX-001, une plate-forme de livraison de nanoparticules muco-adhésives biodégradables, capable de libérer des médicaments de façon prolongée à des fins ophtalmiques et autres. Tous les droits sur la technologie MyX-001 initialement détenue par AmorChem ont été transférés à MyX Thérapeutique, avec un investissement initial de 450 000 $. Cet investissement permettra à MyX de conclure ses premières transactions avec des partenaires commerciaux, ciblant principalement les maladies oculaires affectant la santé humaine et la santé animale.

Développés par les chercheurs Frank Gu, Lyndon Jones et Sandy Liu, de l’Université de Waterloo, la technologie MyX-001 a démontré son fort potentiel comme plate-forme de livraison ciblée directement à la muqueuse. « Ce système d’administration peut être réglé en fonction des propriétés du médicament afin de maximiser la charge de médicament dans les nanoparticules et d’assurer une libération prolongée pour une efficacité maximale du médicament. Il regroupe les avantages clés de nos concurrents dans une seule plate-forme d’administration de médicaments », explique la Dr Inès Holzbaur, cofondatrice et associée directrice, AmorChem.

« Cette technologie est très prometteuse pour améliorer la santé des patients grâce à la nouvelle approche de libération de médicaments ophtalmiques. Notre partenariat avec AmorChem est un excellent exemple où sont réunis la recherche innovante et l’investissement visionnaire pour créer une entreprise en démarrage avec une technologies de pointe telle que MyX », ajoute Scott Inwood, directeur de la commercialisation à l’Université de Waterloo.

« MyX-001 est une plate-forme spécialement conçue pour offrir une différenciation aux nombreux médicaments génériques très efficaces sur le marché, en facilitant l’assiduité au traitement via la réduction de la fréquence d’administration allant d’une dose par jour ou deux doses par semaines, tout en fournissant hydratation et lubrification au niveau de la muqueuse. De plus, MyX-001 permet d’augmenter le seuil de sécurité de nouveaux médicaments ou d’ajuster leur profil de libération, comme nous l’avons démontré avec les premiers modèles animaux. Il est possible de réduire considérablement la quantité de médicament pour obtenir les mêmes résultats efficaces », commente Gregory L. White, PDG de MyX Thérapeutique.

L’ÉQUIPE DE GESTION DE MyX

À la création de MyX Thérapeutique, AmorChem a nommé Gregory L. White, M.Sc. (Zoologie), M.Sc. (Biochimie/Bio. Mol.), en tant que Président et Chef de la direction, Dr Frank Gu, Ph.D., en tant que Chef des affaires scientifiques et Véronique Bougie en tant que Chef des opérations. Leur mandat consiste à élargir l’utilisation de la plate-forme d’administration MyX-001 à diverses indications médicales et à d’autres applications non-liées à la santé.  

À PROPOS DE MyX THÉRAPEUTIQUE

MyX Therapeutics (www.myxthera.com) est une entreprise en démarrage ayant une plate-forme technologique de livraison ciblant la muqueuse. La compagnie se concentre sur un modèle commercial de partenariat de licences de développement de produits. Sa technologie est une nanoparticule biodégradable adhésive brevetée qui permet à son équipe de créer un secteur de marché différenciant les nouveaux produits pour diverses voies d’administration, notamment ophtalmiques, sublinguales et intranasales, vaginales et gastro-intestinales.

À PROPOS D’AMORCHEM

AmorChem (www.amorchem.com) est un fonds de capital de risque de premier plan qui se consacre à la création d’entreprises des plus prometteuses en sciences de la vie à partir de technologies émanant principalement d’universités et de centres de recherche du Québec. Avec 95 M $ sous gestion, AmorChem cible des percées technologiques ayant un impact majeur sur la santé des patients et favorisent leur cheminement jusqu’au stade clinique.

Contacts média

Inès Holzbaur, Ph.D.

Cofondatrice et associée directrice, AmorChem

T:  +1-514-849-7696

E : ines@amorchem.com

 

Gregory L. White, M.Sc., M.Sc.

Président et Chef de la direction, MyX Thérapeutique Inc.

T:  +1-514-797-8833

E:  greg@myxthera.com

HEAD OFFICE

1-800 Westmount Square Montreal, Qc Canada, H3Z 2P9

EMAIL US

info@myxthera.com